Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2
Scheen, André; Mathieu, C.; Nobels, F.
2015 • In Revue Médicale de Liège, 70 (9), p. 423-431
General practitioner; Insulin glargine; Insulin therapy; Type 2 diabetes; Article; Belgian; Belgium; Diabetes Mellitus, Type 2; Aged; Blood Glucose; Female; Follow-Up Studies; General Practice; Humans; Hypoglycemia; Hypoglycemic Agents; Insulins; Male; Middle Aged; Prospective Studies
Abstract :
[en] Initiating or intensifying insulin therapy is often considered as a challenge in general practice. The observational prospective Belgian study InsuStar was performed in 2011-2013 among 150 representative general practitioners, who were invited to initiate or intensify insulin therapy when necessary in 523 patients with type 2 diabetes (mean age : 65.5 years; mean HbA1c : 8.8 %). The initiation of insulin therapy (glargine in > 50 %) was justified by insufficient glycaemic control (96 %) and its intensification (replacement of insulin NPH or premixed insulins by insulin glargine, eventually with the addition of a short-acting insulin analogue) aimed at improving glucose control (58 %), avoiding hypoglycaemia (17 %) or both (17 %). After a follow up of 6 ± 1 months, HbA1c level decreased from 8.79% to 7.52% (-1.27 %; 95 % confidence interval : -1.43,-1.11; p<0.001). Overall 27.6 % of patients reached an HbA1c < 7% versus 5.9 % at inclusion (p<0.001), with rather few hypoglycaemia and a high physician confidence level regarding insulin therapy. These results should encourage general practitioners to initiate insulin therapy at an earlier stage and to intensify it when necessary in patients with insufficiently controlled type 2 diabetes.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Mathieu, C.; Service d'Endocrinologie, UZ Gasthuisberg, Leuven, Belgium
Nobels, F.; Service d'Endocrino-Diabétologie, Onze-Lieve-Vrouw, Aalst, Belgium
Language :
French
Title :
Instauration et optimisation d'une insulinothérapie en médecine générale : InsuStar, une étude observationnelle prospective belge dans le diabète de type 2
Alternative titles :
[en] Initiating and intensifying insulin therapy in general practice: InsuStar, an observational Belgian prospective study in type 2 diabetes
Scheen AJ, Paquot N. Le diabète de type 2 : Voyage au coeur d'une maladie complexe. Rev Med Liège, 2012, 67, 326-331.
Fery F, Paquot N. Etiopathogénie et physiopathologie du diabète de type 2. Rev Med Liège, 2005, 60, 361-368.
Scheen AJ, Mathieu C. Recommandations 2012 en diabétologie. Prise en charge de l'hyperglycémie dans le diabète de type 2 : Une approche centrée sur le patient. Rev Med Liège, 2012, 67, 623-631.
Scheen AJ, Paquot N. Actualisation 2015 des recommandations américaines et européennes pour le traitement du diabète de type 2. Rev Med Liège, 2015, 70, 122-128.
Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 2005, 28, 2673-2679.
Philips JC, Scheen AJ. Inertie clinique dans la prise en charge du patient diabétique de type 2 : Quelles solutions proposer? Rev Med Liège, 2010, 65, 318-325.
Balkau B, Bouee S, Avignon A, et al. Type 2 diabetes treatment intensification in general practice in France in 2008-2009: The DIAttitude Study. Diabetes Metab, 2012, 38 (Suppl 3), S29-35.
Avignon A, Attali C, Sultan A, et al. Clinical inertia: Viewpoints of general practitioners and diabetologists. Diabetes Metab, 2012, 38 (Suppl 3), S53-58.
Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: An integrative review. Adv Med Educ Pract, 2014, 5, 141-147.
Philips JC, Radermecker RP. L'insulinothérapie dans le diabète de type 1. Rev Med Liège, 2005, 60, 322-328.
Home P, Riddle M, Cefalu WT, et al. Insulin therapy in people with type 2 diabetes: Opportunities and challenges? Diabetes Care, 2014, 37, 1499-1508.
Sunaert P, Willems S, Feyen L, et al. Engaging GPs in insulin therapy initiation: A qualitative study evaluating a support program in the Belgian context. BMC Fam Pract, 2014, 15, 144.
Scheen AJ. Comment je traite... un patient diabétique de type 2 : Le projet DREAM pour une meilleure collaboration médecin généraliste-médecin spécialiste. Diabetes Reinforcement of Adequate Management. Rev Med Liège, 1998, 53, 58-62.
Scheen AJ, Bruwier G, Schmitt H. Optimalisation de la prise en charge du patient diabétique de type 2 : Résultats de l'étude DREAM en médecine générale. Rev Med Liège, 2003, 58, 139-146.
Sunaert P, Bastiaens H, Nobels F, et al. Effectiveness of the introduction of a Chronic Care Model-based program for type 2 diabetes in Belgium. BMC Health Serv Res, 2010, 10, 207.
Borgermans L, Goderis G, Van Den Broeke C, et al. Interdisciplinary diabetes care teams operating on the interface between primary and specialty care are associated with improved outcomes of care: Findings from the Leuven Diabetes Project. BMC Health Serv Res, 2009, 9, 179.
Sunaert P, Bastiaens H, Feyen L, et al. Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: the Belgian experience. BMC Health Serv Res, 2009, 9, 152.
Nobels F, Scheen AJ. Le rôle des centres de convention du diabète en Belgique. Rev Med Liège, 2005, 60, 619-623.
Debacker N, Nobels F, Vandenberghe H, et al. Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience. Diabet Med, 2008, 25, 179-185.
Nobels F, Mathieu C, Scheen AJ. Instauration et optimisation d'une insulinothérapie dans le diabète de type 2 (DT2) en médecine générale : Résultats d'une étude observationnelle nationale belge. Diabetes Metab, 2015, 41 (Suppl 1), A120, P342.
Kostev K, Rathmann W. Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: A retrospective database analysis in Germany, France, and UK. Prim Care Diabetes, 2013, 7, 167-171.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med, 2003, 348, 383-393.
Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin, 2011, 27, 887-895.
Balkau B, Calvi-Gries F, Freemantle N, et al. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. Diabetes Res Clin Pract, 2015, 108, 432-440.
Penfornis A, San-Galli F, Cimino L, et al. Current insulin therapy in patients with type 2 diabetes: Results of the ADHOC survey in France. Diabetes Metab, 2011, 37, 440-445.
Halimi S, Balkau B, Attali C, et al. Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: The DIAttitude Study. Diabetes Metab, 2012, 38 (Suppl 3), S36-46.
Aujoulat I, Jacquemin P, Hermans MP, et al. Clinical inertia in general practice, a matter of debate: A qualitative study with 114 general practitioners in Belgium. BMC Fam Pract, 2015, 16, 13.
Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med, 2012, 29, 682-689.
Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: An updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63, 1743-1778.
Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab, 2010, 12, 772-779.
Mathieu C, Storms F, Tits J, et al. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: The ATLANTIC study. Acta Clin Belg, 2013, 68, 28-33.
Home PD, Dain MP, Freemantle N, et al. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract, 2015, 108, 350-359.
Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study. Diabetes Metab, 2015, 41, 116-125.
Peene B, D'Hooge D, Vandebrouck T, et al. Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium. Acta Clin Belg, 2014, 69, 439-445.
Reach G, Le Pautremat V, Gupta S. Determinants and consequences of insulin initiation for type 2 diabetes in France: Analysis of the National Health and Wellness Survey. Patient Prefer Adher, 2013, 7, 1007-1023.
Goderis G, Borgermans L, Heyrman J, et al. Type 2 diabetes in primary care in belgium: Need for structured shared care. Exp Clin Endocrinol Diabetes, 2009, 117, 367-372.
Goderis G, Van Casteren V, Declercq E, et al. Care trajectories are associated with quality improvement in the treatment of patients with uncontrolled type 2 diabetes: A registry based cohort study. Prim Care Diabetes, 2015, Feb 20. pii: S1751-9918(15)00009-1. doi : 10.1016/j.pcd.2015.01.008. [Epub ahead of print].
Van Casteren VF, Bossuyt NH, Moreels SJ, et al. Does the Belgian diabetes type 2 care trajectory improve quality of care for diabetes patients? Arch Public Health, 2015, 73, 31.
Scheen AJ. Le lixisénatide (Lyxumia®) : Nouvel agoniste des récepteurs du glucagon-like peptide-1 à action préférentiellement post-prandiale. Rev Med Liège, 2014, 69, 102-109.
